LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 33

Search options

  1. Article ; Online: Real-Time Telepathology Is Substantially Equivalent to In-Person Intraoperative Frozen Section Diagnosis.

    Rohr, Joseph M / Ginnebaugh, Kevin / Tuthill, Mark / Pimentel, Jason / Markin, Rodney

    Archives of pathology & laboratory medicine

    2023  Volume 148, Issue 1, Page(s) 68–73

    Abstract: Context.—: Intraoperative diagnosis by frozen section is a mainstay of surgical pathology practice, providing immediate feedback to the surgical team. Despite good accuracy with modern methods, access to intraoperative surgical pathology with an ... ...

    Abstract Context.—: Intraoperative diagnosis by frozen section is a mainstay of surgical pathology practice, providing immediate feedback to the surgical team. Despite good accuracy with modern methods, access to intraoperative surgical pathology with an appropriate turnaround time (TAT) has been a limiting factor for small or remote surgical centers, with negative impacts on cost and patient care. Telepathology offers immediate expert anatomic pathology consultation to sites without an in-house or subspecialized pathologist.
    Objective.—: To assess the utility of live telepathology in frozen section practice.
    Design.—: Frozen section diagnoses by telemicroscopy from 2 tertiary care centers with a combined 3 satellite hospitals were queried for anatomic site, TAT per block, pathologist, and concordance with paraffin diagnosis. TAT and concordance were compared to glass diagnoses in the same period.
    Results.—: For 748 intraoperative diagnoses by telemicroscopy, 694 had TATs with a mean of 18 minutes 56 seconds ± 8 minutes 45 seconds, which was slower than on glass (14 minutes 25 seconds ± 7 minutes 8 seconds, P < .001). Twenty-two (2.89% of available) were discordant, which was not significantly different from the on-glass rate (P = .44) or categorical distribution (P = .31). Two cases (0.27%) had technical failures.
    Conclusions.—: Although in-person diagnoses were statistically faster, the great majority of telemicroscopic diagnoses were returned in less than 20 minutes. This remained true through numerous pathologists, pathology assistants and/or technicians, different hospitals, and during a combined 6 years. The concentration of discordant diagnoses among relatively few pathologists suggests individual comfort with telepathology and/or frozen section diagnosis. In rare cases, technical issues prevented telemicroscopic diagnosis. Overall, this justifies continued use and expansion of telemicroscopic services in primary intraoperative diagnoses.
    MeSH term(s) Humans ; Frozen Sections/methods ; Telepathology/methods ; Pathology, Surgical/methods ; Tertiary Care Centers ; Tomography, X-Ray Computed
    Language English
    Publishing date 2023-03-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 194119-7
    ISSN 1543-2165 ; 0363-0153 ; 0096-8528 ; 0003-9985
    ISSN (online) 1543-2165
    ISSN 0363-0153 ; 0096-8528 ; 0003-9985
    DOI 10.5858/arpa.2022-0261-OA
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date.

    Tacconi, Eliana M C / Tuthill, Mark / Protheroe, Andrew

    OncoTargets and therapy

    2020  Volume 13, Page(s) 12301–12316

    Abstract: In 2018, there were 400,000 new cases of renal cell carcinoma (RCC) globally, with 175,000 deaths attributable to the disease. Three quarters of patients have potentially curable localised disease at diagnosis; however, recurrence rates are as high as 40% ...

    Abstract In 2018, there were 400,000 new cases of renal cell carcinoma (RCC) globally, with 175,000 deaths attributable to the disease. Three quarters of patients have potentially curable localised disease at diagnosis; however, recurrence rates are as high as 40% following surgery. There are currently no adjuvant therapies in routine clinical use which reliably improve outcomes. Effective adjuvant therapy is an urgent unmet need to reduce recurrence risk and improve outcomes. Early efforts explored chemotherapy, radiotherapy, cytokine therapy, hormonal treatments and tumour cell vaccines as adjuvant therapies, however, have yielded disappointing results. More recently, interest shifted to evaluating tyrosine kinase inhibitors (TKIs) in the adjuvant setting, as they improve outcomes in metastatic disease. Five phase III clinical trials testing adjuvant use of a range of TKIs have been performed, with the results of a sixth trial awaited. Unfortunately, these studies have thus far yielded conflicting and disappointing results, and there is currently no strong evidence for routine adjuvant TKI therapy. In parallel, novel immunotherapy treatment approaches have recently been developed, transforming the management of a range of malignancies, particularly through immune checkpoint inhibitors (ICIs). These approaches are well established in the metastatic context in RCC, as well as in the adjuvant treatment of melanoma. On this basis, five phase III trials are currently ongoing to test the efficacy of a range of ICIs in adjuvant RCC patients, with initial results expected over the next few years. In this article, we review the current evidence for adjuvant therapies in RCC, discuss ongoing clinical trials and suggest directions for future work to address this unmet need.
    Language English
    Publishing date 2020-11-30
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2495130-4
    ISSN 1178-6930
    ISSN 1178-6930
    DOI 10.2147/OTT.S174149
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: UniTwain: A Cost-Effective Solution for Lean Gross Imaging.

    Lam, Hansen / Kwan, Ricky / Tuthill, Mark / Haghighi, Mehrvash

    Journal of pathology informatics

    2020  Volume 11, Page(s) 31

    Abstract: Background: Gross imaging of surgical specimens is paramount for the accurate gross examination and diagnosis of disease. Optimized imaging workflow can facilitate consistently high-quality gross photographs, especially in high-volume, metropolitan ... ...

    Abstract Background: Gross imaging of surgical specimens is paramount for the accurate gross examination and diagnosis of disease. Optimized imaging workflow can facilitate consistently high-quality gross photographs, especially in high-volume, metropolitan hospitals such as ours. Most commercial medical gross imaging technology provides ergonomically well-designed hardware, remotely operated cameras, intuitive software interfaces, and automation of workflow. However, these solutions are usually cost-prohibitive and require a large sum of capital budget.
    Materials and methods: We applied lean techniques such as value stream mapping (VSM) to design a streamlined and error-free workflow for gross imaging process. We implemented a cost-effective technology, UniTwain, combined with high-resolution webcam to achieve the ideal results.
    Results: We reduced the mean process time from 600 min to 4.0 min (99.3% decrease in duration); the median process time was reduced from 580 min to 3.0 min. The process efficiency increased from 20% to 100%. The implemented solution has a comparable durability, scalability, and archiving feasibility to commercial medical imaging systems and costs four times less. The only limitations are manual operation of the webcam and lower resolution. The webcam sensors have 8.2 megapixel (MP) resolution, approximately 12 MP less than medical imaging devices. However, we believe that this difference is not visually significant and the effect on gross diagnosis with the naked eye is minimal.
    Conclusions: To our knowledge, this is the first study that utilized UniTwain as a viable, low-cost solution to streamline the gross imaging workflow. The UniTwain combined with high-resolution webcam could be a suitable alternative for our institution that does not plan to heavily invest in medical imaging.
    Language English
    Publishing date 2020-10-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2579241-6
    ISSN 2153-3539 ; 2229-5089
    ISSN (online) 2153-3539
    ISSN 2229-5089
    DOI 10.4103/jpi.jpi_42_20
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Automating anatomic pathology. Implementing an AP solution that integrates with your hospital's LIS can improve workflow and productivity.

    Tuthill, Mark

    Health management technology

    2008  Volume 29, Issue 3, Page(s) 18, 20

    MeSH term(s) Clinical Laboratory Information Systems ; Efficiency, Organizational ; Pathology Department, Hospital ; Systems Integration ; United States
    Language English
    Publishing date 2008-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1204815-x
    ISSN 1074-4770
    ISSN 1074-4770
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Case report of oxalate nephropathy in a patient with pancreatic metastases from renal carcinoma.

    Purshouse, Karin / Chamberlain, Sarah / Soares, Maria / Tuthill, Mark / Protheroe, Andrew / Mole, David R

    BMC cancer

    2019  Volume 19, Issue 1, Page(s) 967

    Abstract: Background: Patients with metastatic renal carcinoma frequently have pre-existing renal impairment and not infrequently develop worsening renal function as a complication of their treatment. The presence of pancreatic metastases in patients with ... ...

    Abstract Background: Patients with metastatic renal carcinoma frequently have pre-existing renal impairment and not infrequently develop worsening renal function as a complication of their treatment. The presence of pancreatic metastases in patients with metastatic renal carcinoma, often confers a more favourable prognosis and as a consequence this patient group may be exposed to such treatments for more prolonged periods of time. However, the development of renal failure may also be a consequence of the cancer itself rather than its treatment.
    Case presentation: We present an 84-year-old patient receiving the tyrosine kinase inhibitor (TKI) pazopanib for metastatic renal carcinoma who developed oxalate nephropathy as a consequence of pancreatic exocrine insufficiency resulting from pancreatic metastases.
    Conclusions: This case demonstrates the importance of investigating unexpected toxicities and highlights the potential consequences of pancreatic insufficiency and its sequelae in patients with pancreatic metastases.
    MeSH term(s) Acetates/therapeutic use ; Aged, 80 and over ; Calcium Compounds/therapeutic use ; Carcinoma, Renal Cell/complications ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/pathology ; Exocrine Pancreatic Insufficiency/complications ; Gastrointestinal Agents/therapeutic use ; Humans ; Indazoles ; Kidney Failure, Chronic/etiology ; Kidney Failure, Chronic/therapy ; Kidney Neoplasms/complications ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/pathology ; Male ; Oxalates/urine ; Pancreatic Neoplasms/complications ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/secondary ; Pancrelipase/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Pyrimidines/adverse effects ; Pyrimidines/therapeutic use ; Renal Dialysis ; Sulfonamides/adverse effects ; Sulfonamides/therapeutic use ; Treatment Outcome
    Chemical Substances Acetates ; Calcium Compounds ; Gastrointestinal Agents ; Indazoles ; Oxalates ; Protein Kinase Inhibitors ; Pyrimidines ; Sulfonamides ; Pancrelipase (53608-75-6) ; pazopanib (7RN5DR86CK) ; calcium acetate (Y882YXF34X)
    Language English
    Publishing date 2019-10-17
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 2041352-X
    ISSN 1471-2407 ; 1471-2407
    ISSN (online) 1471-2407
    ISSN 1471-2407
    DOI 10.1186/s12885-019-6215-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease.

    Doyle, Emma / Crew, Jeremy / Mostafid, Hugh / Tuthill, Mark / Cerundolo, Vincenzo / Gerristen, Winald / Protheroe, Andrew

    BJU international

    2019  Volume 123, Issue 6, Page(s) 947–958

    Abstract: Aim: This narrative review describes current guidelines for treating NMIBC, provides an overview of the principle behind immune checkpoint inhibition, and summarizes current evidence for checkpoint inhibitors in urothelial malignancy. Further, we ... ...

    Abstract Aim: This narrative review describes current guidelines for treating NMIBC, provides an overview of the principle behind immune checkpoint inhibition, and summarizes current evidence for checkpoint inhibitors in urothelial malignancy. Further, we discuss potential strategies for immune checkpoint inhibition in the management of NMIBC.
    Background: Adjuvant intravesical BCG immunotherapy has been the mainstay of treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) for decades but is associated with both a significant side effect profile and failure rate. Recently, a substantial body of trial data has been published demonstrating the successful use of systemic immunotherapy in the treatment of advanced urothelial malignancy and, in particular, a class of drugs known as 'immune checkpoint inhibitors'. This has led to the approval of a number of these drugs by the UK National Institute of Health and Care Excellence and the US Food and Drug Administration, and ongoing trials are examining use in the management of NMIBC.
    Methods: To identify relevant published data, using the PubMed/ Medline search engine, an online search of the Pubmed/ Medline archives was conducted using the terms bladder cancer' in combination with 'checkpoint inhibitors', and limited to articles in English published between 1966 and September 2017.To identify ongoing trials of interest but not yet published, a further search of the clinical trials.gov search engine was conducted using the term 'non-muscle-invasive bladder cancer'.
    Conclusion: There has been little advance in available adjuvant therapy for NMIBC treated with TURBT. Current intravesical therapies are associated with a high recurrence rate and significant side effect profile. The impending publication of the wealth of ongoing trials, both into the delivery and efficacy of checkpoint inhibition will direct the future treatment of NMIBC.
    MeSH term(s) Administration, Intravesical ; Antineoplastic Agents, Immunological/therapeutic use ; BCG Vaccine/therapeutic use ; Cystectomy ; Humans ; Immunologic Factors/therapeutic use ; Immunotherapy ; Urinary Bladder Neoplasms/pathology ; Urinary Bladder Neoplasms/therapy ; Urothelium
    Chemical Substances Antineoplastic Agents, Immunological ; BCG Vaccine ; Immunologic Factors
    Language English
    Publishing date 2019-01-22
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1462191-5
    ISSN 1464-410X ; 1464-4096 ; 1358-8672
    ISSN (online) 1464-410X
    ISSN 1464-4096 ; 1358-8672
    DOI 10.1111/bju.14643
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Structuring data in anatomic pathology reports

    Mammen Joy / Tuthill Mark

    Indian Journal of Pathology and Microbiology, Vol 52, Iss 3, Pp 450-

    2009  Volume 451

    Keywords Pathology ; RB1-214 ; Medicine ; R ; DOAJ:Pathology ; DOAJ:Medicine (General) ; DOAJ:Health Sciences ; Microbiology ; QR1-502 ; Science ; Q ; DOAJ:Microbiology ; DOAJ:Biology ; DOAJ:Biology and Life Sciences
    Language English
    Publishing date 2009-07-01T00:00:00Z
    Publisher Medknow Publications
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article: Hematopoietic stem cell transplantation.

    Hatzimichael, Eleftheria / Tuthill, Mark

    Stem cells and cloning : advances and applications

    2010  Volume 3, Page(s) 105–117

    Abstract: More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital metabolic defects, hemoglobinopathies, and myelodysplastic and myeloproliferative ... ...

    Abstract More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital metabolic defects, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes. Before transplantation, patients receive intensive myeloablative chemoradiotherapy followed by stem cell "rescue." Autologous HSCT is performed using the patient's own hematopoietic stem cells, which are harvested before transplantation and reinfused after myeloablation. Allogeneic HSCT uses human leukocyte antigen (HLA)-matched stem cells derived from a donor. Survival after allogeneic transplantation depends on donor-recipient matching, the graft-versus-host response, and the development of a graft versus leukemia effect. This article reviews the biology of stem cells, clinical efficacy of HSCT, transplantation procedures, and potential complications.
    Language English
    Publishing date 2010-08-26
    Publishing country New Zealand
    Document type Journal Article ; Review
    ISSN 1178-6957
    ISSN 1178-6957
    DOI 10.2147/SCCAA.S6815
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Structuring data in anatomic pathology reports.

    Mammen, Joy J / Tuthill, Mark J

    Indian journal of pathology & microbiology

    2009  Volume 52, Issue 3, Page(s) 450–451

    MeSH term(s) Humans ; Pathology/methods ; Research Design/standards
    Language English
    Publishing date 2009-07
    Publishing country India
    Document type Letter
    ZDB-ID 197621-7
    ISSN 0974-5130 ; 0377-4929
    ISSN (online) 0974-5130
    ISSN 0377-4929
    DOI 10.4103/0377-4929.55030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).

    Vasudev, Naveen S / Ainsworth, Gemma / Brown, Sarah / Pickering, Lisa / Waddell, Tom / Fife, Kate / Griffiths, Richard / Sharma, Anand / Katona, Eszter / Howard, Helen / Velikova, Galina / Maraveyas, Anthony / Brown, Janet / Pezaro, Carmel / Tuthill, Mark / Boleti, Ekaterini / Bahl, Amit / Szabados, Bernadett / Banks, Rosamonde E /
    Brown, Joanne / Venugopal, Balaji / Patel, Poulam / Jain, Ankit / Symeonides, Stefan N / Nathan, Paul / Collinson, Fiona J / Powles, Thomas

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2023  Volume 42, Issue 3, Page(s) 312–323

    Abstract: Purpose: Ipilimumab (IPI), in combination with nivolumab (NIVO), is an approved frontline treatment option for patients with intermediate- or poor-risk advanced renal cell carcinoma (aRCC). We conducted a randomized phase II trial to evaluate whether ... ...

    Abstract Purpose: Ipilimumab (IPI), in combination with nivolumab (NIVO), is an approved frontline treatment option for patients with intermediate- or poor-risk advanced renal cell carcinoma (aRCC). We conducted a randomized phase II trial to evaluate whether administering IPI once every 12 weeks (modified), instead of once every 3 weeks (standard), in combination with NIVO, is associated with a favorable toxicity profile.
    Methods: Treatment-naïve patients with clear-cell aRCC were randomly assigned 2:1 to receive four doses of modified or standard IPI, 1 mg/kg, in combination with NIVO (3 mg/kg). The primary end point was the proportion of patients with a grade 3-5 treatment-related adverse event (trAE) among those who received at least one dose of therapy. The key secondary end point was 12-month progression-free survival (PFS) in the modified arm compared with historical sunitinib control. The study was not designed to formally compare arms for efficacy.
    Results: Between March 2018 and January 2020, 192 patients (69.8% intermediate/poor-risk) were randomly assigned and received at least one dose of study drug. The incidence of grade 3-5 trAEs was significantly lower among participants receiving modified versus standard IPI (32.8%
    Conclusion: Rates of grade 3-5 trAEs were significantly lower in patients receiving modified versus standard IPI. Although 12-month PFS did not meet the prespecified efficacy threshold compared with historical control, informal comparison of treatment groups did not suggest any reduction in efficacy with the modified schedule.
    MeSH term(s) Humans ; Nivolumab/therapeutic use ; Ipilimumab ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/pathology ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/pathology
    Chemical Substances Nivolumab (31YO63LBSN) ; Ipilimumab
    Language English
    Publishing date 2023-11-06
    Publishing country United States
    Document type Randomized Controlled Trial ; Clinical Trial, Phase II ; Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.23.00236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top